ABSTRACT. We investigated the efficacy of the oral administration of oseltamivir phosphate (OP) in horses experimentally infected with equine influenza A virus (H3N8). Nine horses were divided into three horses each of control, treatment and prophylaxis groups. An administration protocol for the treatment group (2 mg/kg of body weight, twice a day for five days) was started immediately after the onset of pyrexia (above 38.9°C). An administration protocol for the prophylaxis group (2 mg/kg of body weight, once a day for five days) was started on a day before viral inoculation. In the treatment group, periods of virus excretion (mean days ± standard deviation, 2.3 ± 0.6) and pyrexia (2.0 ± 0.0) were apparently shorter than those of the control group (6.0 ± 0.0 and 8.0 ± 1.0, respectively). In the prophylaxis group, although virus excretion and pyrexia were not prevented, the periods of virus excretion (5.0 ± 0.0) and pyrexia (4.7 ± 1.5) were shorter than those of the control group. Moreover, in the treatment and prophylaxis groups, bacterial counts of Streptococcus equi subsp. zooepidemicus known as the common pathogen of secondary bacterial pneumonia in bronchoalveolar lavage fluids collected seven days after inoculation were significantly fewer than that of the control group. The results indicated that the oral administration of OP to horses affected with equine influenza would contribute to reduce the magnitude of virus excretion, pyrexia and consequent secondary bacterial pneumonia.
Equine influenza A virus (EIV) is one of the most important pathogen of horses, due to its rapid transmission. Horses infected with EIV develop typical respiratory disorders including acute onset of pyrexia, nasal discharge, coughing and depression [1, 17] . Moreover, equine influenza (EI) is often complicated by secondary bacterial infections, which lead to pneumonia [1] . There are two subtypes of EIV, A/Equi 1/H7N7; first isolated in 1956, and A/Equi 2/H3N8, first isolated in 1963. However, it is generally accepted that A/Equi 1/H7N7 has not been isolated since 1979 and might be extinct [17] . In contrast, A/Equi 2/H3N8 still circulates worldwide with the exception of a small number of island countries [17] . EI outbreak results in interruption of equine sports events with financial impact. Especially in Japan, the horse races were cancelled for two months by EI outbreak in 1971, which resulted in the severe economic loss [7] .
Although vaccination strategies are the core of prevention for EI as well as for human influenza, EI vaccination is only partly effective in preventing the disease [10, 17] . At present, stall-rest is the most vital component of treatment for EI to restore the damaged lung [1] . When horses return to training or work before the complete recovery, evil consequences such as myocarditis and chronic obstructive pulmonary disease might occur [1, 17] . To take measure for EI, therefore, the development of chemotherapy for EI would have an important role to complement the vaccination. Rees, W. A. et al. [12, 13] investigated the efficacies of adamantanes (amantadine and rimantadine) for use in horses. However, in humans, the rapid emergence of drug-resistant variants and the toxic effects to the central nervous system limit their clinical utility [8] . Actually, it was reported that amantadine would be difficult to be used in horses because of the narrow safety range of the drug in plasma concentration [13] .
Recently, the newly developed drugs, which inhibit neuraminidase (NA) activity, were introduced into practice to treat and/or prevent human influenza in various countries. One is zanamivir and the other is oseltamivir phosphate (OP). In contrast to the adamantanes, these drugs are associated with very little toxicity and are far less likely to promote the development of drug-resistant virus [8] . Zanamivir must be delivered topically to respiratory tract because of its poor bioavailability [2] . This would limit the use of zanamivir in practice since veterinarians must synchronize the period of administration with the horse's inspiration. On the other hand, OP is an oral prodrug. After oral administration of OP, it is hydrolyzed to its active metabolite [oseltamivir carboxylate (OC)] by hepatic esterases [2] . Since it has been already demonstrated that OC as well as ZA has sufficient efficacy to inhibit the NA activities and viral replications of the several EIV strains (H7N7 and H3N8) in vitro [19] , we speculated that the oral administration of OP to horses affected with EI would be a useful measure in equine veterinary practice for EI.
The aim of this study is to investigate whether the oral administration of OP does in fact work for treatment and/or prophylaxis in horses infected with EIV.
MATERIALS AND METHODS

Animals:
Nine healthy horses (see Table 2 for the breed and sexuality) were randomly divided into 3 groups of 3 horses each, which were named control, treatment and pro-phylaxis groups, respectively. They were approximately one-year-old at the time of this study and had no record of vaccination for EI since birth. A few days prior to this study, these horses were moved into the biosafety level-3 containment facilities of our laboratory and kept there during the study since EI is a foreign disease in Japan. All experimental procedures were approved by the Animal Care Committee of Equine Research Institute.
Protocol: Under sedation with medetomidine hydrochloride, all horses were inoculated by inhalation of A/Equi 2/La Plata/93 [H3N8, 2 × 10 8 50% egg infective doses (EID 50 )] with using the ultrasonic nebulizer (Soniclizer305, ATOM, Tokyo) on Day 0 [9] . The study was conducted until Day 14. Rectal temperatures (RTs) were measured each morning throughout the study. The sera obtained on Days 0, 7 and 14 were measured hemagglutination inhibition (HI) titers against the inoculated virus, as previously described by Imagawa, H. et al. [4] . RT above 38.9°C was defined as pyrexic in this study according to the previous reports by Mumford, J. A. et al. [9, 10] . In the treatment group, oral administration of OP (Tamiflu dry syrup, Chugai Pharmaceutical, Tokyo) was conducted twice a day (12 hr intervals) at 2 mg/kg of body weight for five days from the day when pyrexia was observed. In the prophylaxis group, oral administration of OP was conducted once a day (24 hr intervals) at 2 mg/kg of body weight for five days from Day -1 (a day before viral inoculation). The administration protocols are summarized in Table 1 .
Viral detection and titration: Nasal swabs were taken daily, using 1 × 1.5 cm absorbent cotton with a stick. Swabs were passed via the ventral meatus into the nasopharynx and held there for 1 min to absorb respiratory secretions. Swabs were immersed in the 2.5 ml of lactose broth medium (Nissui, Tokyo) containing 0.004% (w/v) gentamicin sulphate (Gentacin injection, Schering-plough, Osaka) (LBM). Samples were centrifuged at 1,500 × g for 15 min. The supernatants were divided into aliquots and stored below -70°C until analyzed. To detect EIV, 200 µl of the supernatants diluted 1:10 (v/v) in LBM were injected into the allantoic cavity of 10-day-old embryonated hen's eggs (four eggs per sample). The allantoic fluid was harvested after 3 days of incubation at 34°C and tested by hemagglutination using 0.5% hen's red blood cells. If hemagglutination was observed, quantification assays to determine viral titer (log 10 EID 50 /200 µl) of nasal swab specimens were carried out [10, 11] .
Evaluation of lung damage:
Each horse was scored a lung grade (0 to 4) based on lung auscultation, by the method previously described by Rees, W. A. et al. [12] . Briefly, lung grades were scored as follows: 0, sounds typical healthy lung; 1, minor inspiratory wheezes; 2, clearly audible inspiratory wheezes; 3, inspiratory and expiratory wheezes; 4, sounds of mucus shunting (crackles) and severe wheezes. During the experiment, lung grades were scored once each morning.
Bacterial counts in bronchoalveolar lavage fluids: In order to assess the secondary bacterial invasion into lung, bronchoalveolar lavage fluids (BALFs) were collected with a bronchoscope (300 cm long, 8.7 mm diameter, Videobronchoscope, Olympus, Tokyo) from all horses on Days -5 and 7 according to the method of Ito, S. et al. [5] with slight modifications, since the most severe abnormalities by auscultation of lung were observed around 7 days after inoculation of EIV [12] . The bronchi to be lavaged were chosen according to the presence of hyperemia and mucopurulent exudates. The tip of the bronchoscope was wedged in the chosen bronchus. After removal of air from the lavage area, 100 ml of phosphate buffered saline (pH: 7.4) was infused into lung and immediately aspirated manually. This procedure was repeated twice in each bronchus. To minimize contaminations by bacteria and cell debris from bronchi [6] , the BALFs collected at second time lavage in each horse were assessed by standard quantitative cultural methods for the presence of bacteria in alveoli [5] . Identification of bacterial isolates was conducted by using a commercial kit for streptococci (API 20 STREP, BIOMERIÈX, Tokyo). Bacterial counts are expressed as colony forming unit (CFU)/ml of BALF.
Data analysis: All data were analyzed with statistical software (SigmaStat 3.1, Systat Software Inc., CA). RTs were analyzed by two way repeated measures analysis of variance and a multiple test using Student-Newman-Keuls (SNK) method. The periods of pyrexia and virus excretion, lung grade and bacterial count in each group were analyzed by Kruskal-Wallis analysis of variance on ranks and a multiple test using SNK method. Significance was determined at a value of p<0.05.
RESULTS
Confirmation of EIV infection:
All horses used in this study were confirmed to be infected with EIV by serocon- Control -
Oral administration of OP was conducted twice a day at 2 mg/kg of body weight which was actually started from the morning of Day 2. c) Oral administration of OP was conducted once a day at 2 mg/ kg of body weight.
version to inoculated virus (Table 2) , along with the results of viral isolation described below.
Viral detection and titration:
Results of viral detection and titers of the nasal swab specimens collected daily from each horse are represented in Table 3 . EIV began to be detected from all horses from Day 1 or 2. The highest titers of individual horses during the early stage of infection (from Day 1 to 4) were recorded on Day 2 or 3 in the control group and on Day 2 in the treatment and prophylaxis groups. In the treatment group, the viral titers decreased rapidly and no EIV was detected after Day 3, 4 or 5. In the prophylaxis group, the viral titers decreased until Day 4, but re-increased on Day 5. The mean periods (mean days ± standard deviation) of virus excretion in the control, treatment, and prophylaxis groups were 6.0 ± 10.0, 2.3 ± 0.6, and 5.0 ± 0.0, respectively. The period of the treatment group was significantly shorter than those of the control and prophylaxis groups. The period of prophylaxis group was significantly shorter than that of the control group.
Pyrexia: The mean RTs of the three groups are represented in Fig. 1 . Since all horses developed pyrexia on Day 2, the administration of OP was started on the same day in the treatment group. The mean RTs of all groups were dropped below 38.9°C on Day 3, but re-increased from Day 4 or 5. Consequently, bi-phasic febrile responses were observed in all groups. However, the second phases in the three groups showed the difference with various magnitudes. The RTs of the treatment group from Day 5 to 11 Mean rectal temperatures (± standard deviation) of each group. a: Days in which differences between the control and treatment groups were significant (p<0.05). b: Days in which differences between the control and prophylaxis groups were significant (p<0.05). c: Days in which differences between the treatment and prophylaxis groups were significant (p<0.05).
were significantly lower than those of the control group. And the RTs of the prophylaxis group from Day 4 to 7 were significantly lower than those of the control group. Although the RTs of the prophylaxis group were significantly lower than those of the treatment group on Days 4 and 5, the RTs of the prophylaxis group were significantly higher than those of the treatment group from Day 8 to 10. The mean periods (mean days ± standard deviation) of pyrexia in the control, treatment and prophylaxis groups were 8.0 ± 1.0, 2.0 ± 1.0 and 4.7 ± 1.5, respectively. The periods of pyrexia observed in the treatment and prophylaxis groups were significantly shorter than that of the control group.
Evaluation of lung damage:
Scoring results of lung grade in each horse are represented in Table 4 . The lung grades of the control group began to increase from Day 2 or 3 with the peak on Day 7, when all horses showed lung grade 3. The horses in the treatment group showed the minor inspiratory wheezes (lung grade 1) exclusively from Day 3 to 5. In the prophylaxis group, all horses showed lung grade 0 until Day 6, but the lung grades began to increase from Day 7. The median of total lung grades recorded in the treatment group was significantly lower than that recorded in the control or prophylaxis group.
Bacterial counts from BALFs: Bacterial counts in BALFs collected from the horses before experiment and on Day 7 are shown in Table 5 . No bacteria were isolated from BALFs obtained from all horses on Day -5. On Day 7, Streptococcus equi subsp. zooepidemicus (S. zooepidemicus) was exclusively isolated from BALFs of all horses. Bacterial counts (CFU/ml) of the control, treatment and prophylaxis groups were ranged from 4.0 × 10 6 to 2.0 × 10 7 , from 1.2 × 10 4 to 8.0 × 10 5 and from 2.0 × 10 1 to 6.0 × 10 4 , respectively. The median bacterial counts of the treatment and prophylaxis groups on Day 7 were significantly fewer than that of the control group. Whereas, the significant difference was not detected between the median bacterial counts of the treatment and prophylaxis groups.
DISCUSSIONS
This study was designed to assess the therapeutic and prophylactic efficacies of OP in horses. To our knowledge, this is the first reported use of OP in horses. At present, there is no assessment of equine pharmacokinetics of OC after oral administration of OP although orally administered OP would be hydrolyzed to OC in horses as well as in humans [2] . Therefore, according to the human pediatric study described by Whitley, R. J. et al. [18] , a dosage of 2 mg/kg of body weight was adopted in this study. According to the randomized controlled study in adult humans for treatment and prophylaxis described by Hayden, F. G. et al. [3] , the administration schedules (intervals and durations) of the treatment and prophylaxis groups of this study were determined.
It is well known that the bi-phasic febrile response is usually observed in horses affected with EI [1, 9, 16, 17] . We reproduced the clear bi-phasic febrile responses in this study. The initial febrile response is considered to be mainly related with viral replication in the epithelial cells of 1  0  0  0  1  2  2  2  3  2  1  1  1  0  0  0  15  15  Control  2  0  0  0  0  0  1  1  3  3  2  2  0  0  0  0  12  3  0  0  1  2  2  3  3  3  3  3  3  3  1  1  1 the respiratory tract [16, 17] . On the other hand, the second febrile response is considered to be mainly related with the invasion of opportunistic bacterial pathogen into lung due to the damage of respiratory mucociliary escalators by viral replication [16, 17] . In fact, S. zooepidemicus, which is known as one of the most common potential pathogen of secondary bacterial pneumonia following EI [14] , was isolated from the BALFs of all horses on Day 7. At the present study, the second febrile response of the treatment group after Day 4 showed significantly lower magnitude than that of the control group. Furthermore, it was observed that the slight lung abnormality was only recorded for a few days and the median count of S. zooepidemicus in BALFs of the treatment group was significantly fewer than that of the control group. These observations suggest that the treatment with OP would ameliorate the damage of the respiratory mucociliary escalators by EIV. This assumption is supported by the rapid reduction of virus excretion in the treatment group. From the viewpoint of individual management, these findings suggest that the oral administration of OP could decrease the severity of secondary bacterial pneumonia, and thus allow horses affected with EI to return early to training or work. On the other hand, from the viewpoint of herd management, it is noteworthy that the virus excretion disappeared rapidly after the first few days of treatment, suggesting that the oral administration of OP to horses affected with EI could reduce viral spread to other healthy horses. In case of EI outbreak, reduction of viral spread would be meaningful for sanitary management in horse premises including racecourses or riding farms where many horses are kept closely.
In the prophylaxis group of this study, prophylactic administration of OP from Day -1 could not prevent the onset of virus excretion and initial febrile response. However, the second febrile response in the prophylaxis group delayed as compared to the other 2 groups, and the absence of lung abnormality continued until Day 6. Furthermore, the median count of S. zooepidemicus in BALFs of the prophylaxis group collected on Day 7 was significantly fewer than that of the control group. Since the decreases of viral titers were observed on Days 3 and 4 in the prophylaxis group, it is suggested that the prophylactic administration of OP before EIV infection would alleviate the secondary bacterial pneumonia by the suppression of viral replication and its consequent alleviation of the damage to the respiratory mucociliary escalators during the early stage of infection. However, the re-increases of viral titers on Day 5 were observed in the prophylaxis group, and almost simultaneously, the RTs and lung grades began to increase again in this study. This exacerbation seems to be caused by quitting the administration of OP after Day 4. When the onset of symptoms in horses receiving the prophylactic administration of OP is observed, therefore, it would be desirable to prolong the duration of administration or change to the treatment protocol described in this study.
For treatment of human influenza, it is recommended that the administration of OP start within 2 days after the onset of symptoms [2, 8] . Also for treatment of EI, the early administration of OP would be required to obtain satisfactory outcome. To use OP effectively in equine practice, it would be desirable to diagnose EI rapidly with using the rapid diagnostic methods such as the immunoassay kits for antigen detection or reverse transcriptase PCR for viral RNA detection [15, 17] .
In humans, the gastrointestinal abnormalities (e.g. vomiting, nausea and abdominal pain) are known as the common adverse effects of the orally administered OP [8] . At present, the safety of this drug in horses remains unestablished. Although no gastrointestinal abnormality related to the oral administration of OP was observed in the experimental horses during this study, further investigations on the safety of OP in horses would be required.
The results of this study indicated that the oral administration of OP to horses affected with EI would contribute to reduce not only the magnitude of virus excretion and pyrexia, but also the consequent secondary bacterial pneumonia.
